24 completed, 13 recruiting, 6 active not recruiting, 4 terminated. 29 Phase 2, 18 Phase 1, 4 Not applicable, 3 Phase 3, 1 Early Phase 1.
Follow Lymphoplasmacytic Lymphoma: new trials by email Literature Review of Lymphoplasmacytic Lymphoma trials Research Report on Lymphoplasmacytic Lymphoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Connected Blood Pressure Monitoring in Patients With Hematologic Malignancies Initiating Covalent BTK Inhibitors Connected home blood pressure monitoring with daily IPA supervision. - Chronic Lymphocytic Leukemia (CLL), Follicular Lymphoma ( FL) | Not applicable | Not yet recruiting | Centre Hospitalier de la côte Basque | 40 | 2026-07-01 | 2026-06-22 |
| Dose Escalation and Dose Expansion Study of MDX2003 in Patients With Different Types of Lymphoma MDX2003 - Lymphoma, Waldenström Macroglobulinemia (WM) | Phase 1 / Phase 2 | Recruiting | ModeX Therapeutics, An OPKO Health Company | 180 | 2026-04-13 | 2026-05-04 |
| Study to Assess Change in Disease Activity of Oral Venetoclax in Adult Participants With Recurring Relapsed or Refractory (R/R) Waldenström Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Venetoclax - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Active not recruiting | AbbVie | 14 | 2026-03-17 | 2026-09-09 |
| A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia Pacritinib - Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Shayna Sarosiek, MD | 30 | 2025-11-21 | 2025-12-05 |
| A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) Pirtobrutinib, Venetoclax, Rituximab - Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | Phase 2 | Recruiting | Memorial Sloan Kettering Cancer Center | 40 | 2025-11-11 | 2026-09-30 |
| Watch and Wait or Worry and Wait in Indolent Lymphoma Patient-Reported Outcomes Survey - Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL), Marginal Zone Lymphoma(MZL) | Enrolling by invitation | Seoul National University Hospital | 250 | 2025-10-01 | 2025-11-21 | |
| Combating Cancer-Related Fatigue: A Personalized Supportive Care Program Exercise, Diet - Indolent Lymphomas, Lymphoma | Not applicable | Recruiting | UNC Lineberger Comprehensive Cancer Center | 40 | 2025-06-03 | 2026-07-01 |
| 64Cu-LLP2A for Imaging Hematologic Malignancies 64Cu-LLP2A, PET/CT - Multiple Myeloma, Low-Grade Lymphoma | Early Phase 1 | Terminated | Washington University School of Medicine | 21 | 2025-03-20 | 2026-10-16 |
| AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas CD22CART Infusion - Follicular Lymphoma, Mantle Cell Lymphoma | Phase 1 | Recruiting | Stanford University | 148 | 2024-03-29 | 2026-08-12 |
| Study of SGR-1505 in Mature B-Cell Neoplasms SGR-1505 - Mature B-Cell Neoplasm, Non Hodgkin Lymphoma | Phase 1 | Recruiting | Schrödinger, Inc. | 98 | 2023-04-10 | 2026-02-13 |
| Local Manufacture of CAR T-Cell Products for the Treatment of B-Cell Lymphoma and B-Acute Lymphoblastic Leukemia Chimeric Antigen Receptor (CAR) T-Cell Product (Autologous) - B-Cell Lymphoma, B Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | John Lister | 30 | 2022-04-19 | 2025-01-13 |
| HMPL-760 Safety and Tolerability Study in Patients With Previously Treated CLL/SLL or NHL HMPL-760 - CLL/SLL, NHL | Phase 1 | Withdrawn | Hutchmed | 2022-02-15 | 2023-02-21 | |
| Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic Lymphoma Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy - Lymphoplasmacytic Lymphoma, Waldenstrom Macroglobulinemia | Phase 2 | Recruiting | National Cancer Institute (NCI) | 92 | 2022-01-05 | 2026-10-14 |
| Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas Acalabrutinib, Obinutuzumab, Quality-of-Life Assessment - Grade 1 Follicular Lymphoma, Grade 2 Follicular Lymphoma | Phase 2 | Recruiting | Emory University | 49 | 2021-09-03 | 2026-02-09 |
| Testing CC-486 (Oral Azacitidine) Plus the Standard Drug Therapy in Patients 75 Years or Older With Newly Diagnosed Diffuse Large B Cell Lymphoma Biospecimen Collection, Computed Tomography, Cyclophosphamide - Ann Arbor Stage III Diffuse Large B-Cell Lymphoma, Ann Arbor Stage IIX (Bulky) Diffuse Large B-Cell Lymphoma | Phase 2 / Phase 3 | Active not recruiting | National Cancer Institute (NCI) | 422 | 2021-05-20 | 2026-10-01 |
| Immune Responses to COVID-19 Vaccination in Lymphoma Patients Classical Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma | Completed | University Hospital Southampton NHS Foundation Trust | 592 | 2021-03-11 | 2024-02-06 | |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B-Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 16 | 2021-01-21 | 2026-04-08 |
| Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma Fludarabine, Cyclophosphamide, anti-CD19 CAR-T cells - Refractory Non-Hodgkin Lymphoma, Burkitt Lymphoma | Phase 1 | Recruiting | C. Babis Andreadis | 36 | 2020-09-11 | 2026-06-22 |
| CLBR001 and SWI019 in Patients With Relapsed / Refractory B-cell Malignancies CLBR001 and SWI019 - Relapsed/Refractory B-cell Lymphomas, Diffuse Large B Cell Lymphoma (DLBCL) | Phase 1 | Completed | Calibr, a division of Scripps Research | 18 | 2020-08-14 | 2024-08-20 |
Showing 20 of 52. Sign in to see all of them.
Lymphoma, B-Cell, Marginal Zone (52) · Lymphoma, Follicular (36) · Leukemia, Lymphocytic, Chronic, B-Cell (35) · Lymphoma, Mantle-Cell (32) · Waldenstrom Macroglobulinemia (24) · Burkitt Lymphoma (20) · Lymphoma, Large B-Cell, Diffuse (17) · Lymphoma, Non-Hodgkin (14) · Leukemia, Myeloid, Acute (11) · Lymphoma (11) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (11) · Leukemia, Myelogenous, Chronic, BCR-ABL Positive (10) · Multiple Myeloma (9) · Leukemia, Prolymphocytic (8) · Lymphoma, B-Cell (7)
Hemic and Lymphatic Diseases (52) · Immune System Diseases (52) · Lymphatic Diseases (52) · Neoplasms by Histologic Type (52) · Immunoproliferative Disorders (51) · Lymphoproliferative Disorders (49) · Neoplasms (48) · Hematologic Diseases (47) · Lymphoma, B-Cell (45) · Lymphoma (41) · Lymphoma, Non-Hodgkin (38) · Disease Attributes (37) · Pathologic Processes (37) · Pathological Conditions, Signs and Symptoms (37) · Chronic Disease (36)
Cyclophosphamide (10) · fludarabine (10) · Whole-Body Irradiation (8) · Rituximab (6) · fludarabine phosphate (6) · Mycophenolic Acid (5) · CT-P10 (3) · Cyclosporine (3) · Magnetic Resonance Spectroscopy (3) · venetoclax (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Antilymphocyte Serum (2) · Automobiles (2) · Bortezomib (2) · Cord Blood Stem Cell Transplantation (2)
Masonic Cancer Center, University of Minnesota (8) · Calibr, a division of Scripps Research (2) · Dana-Farber Cancer Institute (2) · Fred Hutchinson Cancer Center (2) · National Cancer Institute (NCI) (2) · Seoul National University Hospital (2) · AbbVie (1) · Alexey Danilov, MD (1) · C. Babis Andreadis (1) · Celldex Therapeutics (1) · Cellectar Biosciences, Inc. (1) · Centre Hospitalier de la côte Basque (1) · City of Hope Medical Center (1) · Emory University (1) · French Study Group on Chronic Lymphoid Leukemia (1)
United States (43) · France (5) · Poland (4) · Australia (3) · Italy (3) · Spain (3) · United Kingdom (3) · Israel (2) · South Korea (2) · Brazil (1) · China (1) · Czechia (1) · Finland (1) · Germany (1) · Greece (1)
Claudio Brunstein, MD, PhD (2) · Steven P. Treon, MD, MA, PhD (2) · Adrian U Wiestner, M.D. (1) · Ajay K. Gopal (1) · Alexey V Danilov (1) · Ann E. Dahlberg (1) · Carrie Ho, MD (1) · Christopher Jensen, MD MSCR (1) · Claudio Brunstein, MD (1) · Craig Okada, M.D. (1) · Elizabeth A Brem (1) · Erica Warlick, MD (1) · Farrokh Dehdashti, M.D. (1)
PMID 34515338, PMID 17242396, PMID 18713945, PMID 21566092, PMID 23065509, PMID 23233721, PMID 24450858, PMID 25016003, PMID 29439670, PMID 33297794, PMID 33516721, PMID 34196037, PMID 34686472, PMID 34780125, PMID 35135810, PMID 35332334, PMID 35358998, PMID 36385536, PMID 36442911, PMID 37331194, PMID 37467318, PMID 40422524, PMID 41980020
U10CA180888 (2), P30CA015083 (1), P30CA033572 (1), P30CA138292 (1), R35CA197353 (1), R42CA257797 (1)